Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study

被引：0
作者：
Cicardi, M. [1 ]
Shennak, M. [2 ]
Zaragoza-Urdaz, R. H. [3 ]
Wang, Y. [4 ]
Lu, P. [4 ]
机构：
[1] Univ Milan, Dept Biomed & Clin Sci, ASST Fatebenefratelli Sacco, Luigi Sacco, Milan, Italy
[2] Triumpharma, Amman, Jordan
[3] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA
[4] Shire, Lexington, MA USA
来源：
ALLERGY | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1428
引用
收藏
页码：722 / 722
页数：1
相关论文
共 50 条
  • [41] Real-world effectiveness of lanadelumab in European patients with HAE type I/II: Results from the retrospective integrated study
    Magerl, M.
    Bouillet, L.
    Saguer, I. Martinez
    Gavini, F.
    Andresen, I.
    Bent-Ennakhil, N.
    Sayegh, L.
    ALLERGY, 2023, 78 : 146 - 146
  • [42] Modeling Pharmacokinetics and Pharmacodynamics on a Mobile Device to Help Caffeine Users
    Ritter, Frank E.
    Yeh, Kuo-Chuan
    FOUNDATIONS OF AUGMENTED COGNITION: DIRECTING THE FUTURE OF ADAPTIVE SYSTEMS, 2011, 6780 : 528 - 535
  • [43] HAE - New Data confirm the Chance of Freedom from Attacks in Prophylaxis Patients who are using Lanadelumab
    不详
    ALLERGO JOURNAL, 2020, 29 (01) : 61 - 61
  • [44] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Sheng Feng
    Ji Jiang
    Pei Hu
    Jian-yan Zhang
    Tao Liu
    Qian Zhao
    Bi-lu Li
    Acta Pharmacologica Sinica, 2012, 33 : 1353 - 1358
  • [45] A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjects
    Feng, Sheng
    Jiang, Ji
    Hu, Pei
    Zhang, Jian-yan
    Liu, Tao
    Zhao, Qian
    Li, Bi-lu
    ACTA PHARMACOLOGICA SINICA, 2012, 33 (11) : 1353 - 1358
  • [46] Efficacy of lanadelumab is durable over time: Findings from the HELP Study and HELP OLE
    Kiani-Alikhan, S.
    Riedl, M.
    Bernstein, J. A.
    Anderson, J.
    Tachdjian, R.
    Lu, P.
    Ren, H.
    Aygoeren-Puersuen, E.
    ALLERGY, 2020, 75 : 59 - 59
  • [47] Lanadelumab prophylaxis reduces breakthrough hereditary angioedema attacks and the need for rescue medication: Exploratory findings from the phase 3 HELP study
    Cicardi, M.
    Maurer, M.
    Longhurst, H. J.
    Johnston, D. T.
    Li, H. H.
    Nurse, C.
    Lu, P.
    Busse, P. J.
    ALLERGY, 2019, 74 : 212 - 212
  • [48] Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study
    Lumry, William R.
    Weller, Karsten
    Magerl, Markus
    Banerji, Aleena
    Longhurst, Hilary J.
    Riedl, Marc A.
    Lewis, Hannah B.
    Lu, Peng
    Devercelli, Giovanna
    Jain, Gagan
    Maurer, Marcus
    ALLERGY, 2021, 76 (04) : 1188 - 1198
  • [49] A phase IIa study to evaluate the safety, pharmacodynamics and pharmacokinetics of TGN255 in stable haemodialysis patients
    Combe, Sophie
    DSouza, Richard
    Mysliwiec, Michal
    Padmanabhan, Neal
    Thomas, Mark
    Villa, Giuseppe
    Will, Eric
    Patrick, Guy
    Kennedy, Anthony
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 215 - 216
  • [50] Cetuximab given every 2 weeks in patients with MCRC: A phase I safety, pharmacokinetics and pharmacodynamics study
    Vega-Villegas, M.
    Cervantes, A.
    Martinelli, E.
    Casado, E.
    Rodriguez-Braun, E.
    Rivera, F.
    Rojo, F.
    Weber, D.
    Baselga, J.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2007, 18 : VII31 - VII31
12345